Relapse of chronic phase chronic myeloid leukemia (CML) on imatinib: BCR-ABL kinase domain mutations conferring drug resistance are frequently detectable prior to clinical evidence of relapse.

被引：0
|
作者：
Shah, NP [1 ]
Nicoll, JM [1 ]
Paquette, RL [1 ]
Sawyers, CL [1 ]
机构：
[1] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Dept Med,Div Hematol Oncol, Los Angeles, CA 90024 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1418
引用
收藏
页码：366A / 366A
页数：1
相关论文
共 50 条
  • [21] Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    Shah, NP
    Nicoll, JM
    Nagar, B
    Gorre, ME
    Paquette, RL
    Kuriyan, J
    Sawyers, CL
    CANCER CELL, 2002, 2 (02) : 117 - 125
  • [22] BCR-ABL kinase domain mutations & SNPs in imatinib resistant or intolerant chronic myeloid leukaemia patients
    O'Connor, Lisa M.
    Langabeer, Stephen
    McCann, Shaun R.
    Conneally, Eibhlin
    BLOOD, 2007, 110 (11) : 699A - 700A
  • [23] Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
    Sun, Xiaoyan
    Cai, Xueting
    Yang, Jie
    Chen, Jiao
    Guo, Caixia
    Cao, Peng
    MOLECULES AND CELLS, 2016, 39 (12) : 869 - 876
  • [24] BCR-ABL gene amplification causes reversible cytogentic relapse and resistance to imatinib (STI571) in a chronic phase CML patient
    Gambacorti-Passeri, C
    Bambacorti-Passeri, C
    Bungaro, S
    Cazzanagi, G
    Piazza, R
    Tornaghi, L
    Pogliani, E
    Alberti, D
    Bondi, A
    Varella-Garcia, M
    Corneo, G
    BLOOD, 2002, 100 (11) : 216B - 216B
  • [25] EVALUATION OF BCR-ABL MONITORING IN CHRONIC MYELOID LEUKEMIA (CML) IN CLINICAL PRACTICE
    Romvari, Edie
    Bollu, Vamsi
    Morlock, Robert
    Teitelbaum, April
    Henk, Henry
    Garcia, Reynaldo
    ONCOLOGY NURSING FORUM, 2011, 38 (02) : E160 - E161
  • [26] PREVALENCE OF BCR-ABL IMATINIB RESISTANT MUTATIONS IN PORTUGUESE CHRONIC MYELOID LEUKAEMIA (CML) PATIENTS
    Palmeiro, A.
    Torres, F.
    Lemos, R.
    Teixeira, M.
    Gabriel, H.
    Rendeiro, P.
    Tavares, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 539 - 539
  • [27] Examination of point mutations within the ABL kinase domain of Bcr-Abl fusion gene in Chinese patients with chronic myeloid leukemia who develop imatinib resistance
    Yang, Dongguang
    Zhang, Ri
    Gang, Honglin
    Gu, Jian
    Cen, Jian Nong
    BLOOD, 2007, 110 (11) : 214B - 215B
  • [28] Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Kim, Dong-Wook
    Martinelli, Giovanni
    Hughes, Timothy P.
    Soverini, Simona
    Branford, Susan
    Muller, Martin C.
    Erben, Philipp
    Haque, Ariful
    Shou, Yaping
    Saglio, Giuseppe
    Radich, Jerald P.
    BLOOD, 2008, 112 (11) : 1103 - 1104
  • [29] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    Jabbour, E.
    Kantarjian, H.
    Jones, D.
    Talpaz, M.
    Bekele, N.
    O'Brien, S.
    Zhou, X.
    Luthra, R.
    Garcia-Manero, G.
    Giles, F.
    Rios, M. B.
    Verstovsek, S.
    Cortes, J.
    LEUKEMIA, 2006, 20 (10) : 1767 - 1773
  • [30] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    E Jabbour
    H Kantarjian
    D Jones
    M Talpaz
    N Bekele
    S O'Brien
    X Zhou
    R Luthra
    G Garcia-Manero
    F Giles
    M B Rios
    S Verstovsek
    J Cortes
    Leukemia, 2006, 20 : 1767 - 1773
12345